Clovis Oncology Inc (CLVS) : Pointstate Capital Lp scooped up 92,280 additional shares in Clovis Oncology Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 15, 2016. The investment management firm now holds a total of 3,596,180 shares of Clovis Oncology Inc which is valued at $60,667,557.Clovis Oncology Inc makes up approximately 1.55% of Pointstate Capital Lp’s portfolio.
Other Hedge Funds, Including , Virtus Etf Advisers reduced its stake in CLVS by selling 473 shares or 5.91% in the most recent quarter. The Hedge Fund company now holds 7,526 shares of CLVS which is valued at $126,964. Clovis Oncology Inc makes up approx 0.15% of Virtus Etf Advisers’s portfolio.
Clovis Oncology Inc closed down -1.18 points or -4.76% at $23.59 with 27,16,679 shares getting traded on Thursday. Post opening the session at $25.01, the shares hit an intraday low of $23.138 and an intraday high of $25.3 and the price fluctuated in this range throughout the day.Shares ended Thursday session in Red.
On the company’s financial health, Clovis Oncology Inc reported $-2.07 EPS for the quarter, beating the analyst consensus estimate by $ 0.04 according to the earnings call on Aug 8, 2016. Analyst had a consensus of $-2.11.During the same quarter in the previous year, the company posted $-2.10 EPS.
Many Wall Street Analysts have commented on Clovis Oncology Inc. Company shares were Reiterated by Mizuho on Aug 24, 2016 to “Neutral”, Firm has raised the Price Target to $ 23 from a previous price target of $15 .Clovis Oncology Inc was Initiated by SunTrust to “Buy” on Aug 5, 2016.
Clovis Oncology Inc. (Clovis) is a biopharmaceutical company focused on acquiring developing and commercializing anti-cancer agents in the United States Europe and additional international markets. The Company is developing three product candidates: Rociletinib Rucaparib and Lucitanib. Rociletinib an oral epidermal growth factor receptor (EGFR) is a mutant-selective covalent inhibitor that is in advanced clinical development for the treatment of non-small cell lung cancer. Rucaparib an oral inhibitor of poly (ADP-ribose) polymerase (PARP) is in advanced clinical development for the treatment of ovarian cancer. Lucitanib is an oral potent inhibitor of the tyrosine kinase activity of fibroblast growth factor receptors 1-3 (FGFR1-3) vascular endothelial growth factor receptors 1-3 (VEGFR1-3) and platelet-derived growth factor receptors alpha and beta (PDGFR a/B) that is in Phase II development for the treatment of breast and lung cancers.